Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Josué M. J. Ramírez-Reyes"'
Autor:
Mathieu Paquette, Ming Yan, Josué M. J. Ramírez-Reyes, Leeanna El-Houjeiri, Marco Biondini, Catherine R. Dufour, Hyeonju Jeong, Alain Pacis, Vincent Giguère, Jennifer L. Estall, Peter M. Siegel, Étienne Audet-Walsh, Arnim Pause
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide and can progress to non-alcoholic steatohepatitis (NASH), which is characterized by triglyceride accumulation, inflammation, and fibrosis. No pharmacologi
Externí odkaz:
https://doaj.org/article/1475e426b13d4372960b3695a52f08dd
Autor:
Josué M. J. Ramírez-Reyes, Ming Yan, Jennifer L. Estall, Catherine R. Dufour, Arnim Pause, Alain Pacis, Étienne Audet-Walsh, Hyeonju Jeong, Mathieu Paquette, Vincent Giguère, Leeanna El-Houjeiri, Marco Biondini, Peter M. Siegel
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Scientific Reports
Scientific Reports
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease worldwide and can progress to non-alcoholic steatohepatitis (NASH), which is characterized by triglyceride accumulation, inflammation, and fibrosis. No pharmacological agent
Autor:
Marco Biondini, Mathieu Paquette, Leeanna El-Houjeiri, Jennifer L. Estall, Ming Yan, Alain Pacis, Hyeonju Jeong, Arnim Pause, Peter M. Siegel, Josué M. J. Ramírez-Reyes
Non-alcoholic steatohepatitis (NASH) represents a major economic burden and is characterized by triglyceride accumulation, inflammation, and fibrosis. No pharmacological agents are currently approved to treat this condition. Emerging data suggests an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f064ee3c0d2828eb8fd2abae6a3f006
https://doi.org/10.1101/2020.09.10.291617
https://doi.org/10.1101/2020.09.10.291617